Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography

Clin Imaging. 2015 May-Jun;39(3):390-5. doi: 10.1016/j.clinimag.2014.12.002. Epub 2014 Dec 12.

Abstract

Objective: The objective was to evaluate diagnostic performance of dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography in differentiating primary central nervous system lymphoma (PCNSL) and glioblastoma.

Materials and methods: Twenty-three glioblastomas and 11 PCNSLs were analyzed with uncorrected cerebral blood volume (CBV) ratio, fifth percentile value of cumulative apparent diffusion coefficient histogram (ADC5%), and maximum standardized uptake value (SUVmax) using regions of interest created semiautomatically on enhancing areas.

Results: Uncorrected CBV ratio was highly capable of differentiating PCNSL from glioblastoma, as well as SUVmax and ADC5%.

Conclusions: Uncorrected CBV ratio demonstrates high diagnostic performance comparable to SUVmax.

Keywords: (18)F-fluorodeoxyglucose positron emission tomography; Diffusion-weighted imaging; Dynamic susceptibility-contrast perfusion-weighted imaging; Glioblastoma; Primary central nervous system lymphoma.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Brain / diagnostic imaging
  • Brain / pathology
  • Brain Neoplasms / diagnosis*
  • Diagnosis, Differential
  • Diffusion Magnetic Resonance Imaging / methods*
  • Female
  • Fluorodeoxyglucose F18
  • Glioblastoma / diagnosis*
  • Humans
  • Lymphoma / diagnosis*
  • Male
  • Middle Aged
  • Perfusion Imaging / methods*
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals
  • Sensitivity and Specificity
  • Young Adult

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18